Expression Profile of MicroRNAs in Breast Milk of Women With Inflammatory Bowel Disease: Correlation With Disease Activity and Medical Treatments
Inflammatory Bowel Diseases · 2025
DOI: 10.1093/ibd/izae290 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2025. Verfasst von Regina Golan-Gerstl und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hebrew University Hadassah Medical Center, Jerusalem, Israel. Hauptthemen laut MEDLINE: Milk, Human, MicroRNAs, Colitis, Ulcerative, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Kenneth Rainin Foundation, Israel Science Foundation.
Abstract (Originalsprache)
Background
Although most inflammatory bowel disease (IBD) medications are considered safe during pregnancy, their impact on microRNAs (miRNAs) in breast milk is largely unknown. MiRNAs in milk, carried by milk-derived extracellular vesicles (MDEs), are transmitted to the newborn’s gut to regulate genes. Aberrant miRNA expression profiles have been found in IBD within tissue, blood, and feces, but data on mother’s milk are scarce.
Methods
We collected breast milk samples from 32 mothers with Crohn’s disease (CD), 14 mothers with ulcerative colitis (UC), and 44 healthy controls. We analyzed miRNA expression through qualitative real-time polymerase chain reaction and Affymetrix miRNA chips. Target genes of differentially expressed miRNAs were predicted using miRATBase. Statistical analyses were conducted using GraphPad Prism software with Mann–Whitney tests.
Results
Milk-derived extracellular vesicles from mothers with IBD showed altered miRNA profiles compared to controls. Specifically, miR-21 and miR-320 were downregulated, while Let-7a was upregulated in IBD mothers. The expression patterns varied between CD and UC, with significantly lower MiR-21 in UC and higher Let-7a in CD. Additionally, anti-tumor necrosis factor treatment during pregnancy was associated with reduced miR-21 and miR-148a levels in MDEs. Pathway analysis revealed that these miRNAs are involved in immune regulation, particularly interleukin signaling pathways.
Conclusions
This study highlights that miRNAs in breast milk are differentially expressed in mothers with IBD, influenced by the disease and its treatments. These findings emphasize the impact of maternal health on milk composition and potential implications for infant immune development. Understanding these findings may guide personalized treatment strategies for mothers and promote breastfeeding among mothers with IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Hebrew University Hadassah Medical Center, Jerusalem, Israel.
- Digestive Diseases Institute, Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem, Israel.
ORCID-Profile: Regina Golan-Gerstl
Förderung
- Kenneth Rainin Foundation
- Israel Science Foundation
Zitieren
APA
Golan-Gerstl, R., Ben Ya'acov, A., Musseri, M., Goldenberg, R., Chammah, Y., Cherki, T., Reif, S., & Bar Gil Shitrit, A. (2025). Expression Profile of MicroRNAs in Breast Milk of Women With Inflammatory Bowel Disease: Correlation With Disease Activity and Medical Treatments. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izae290
Vancouver
Golan-Gerstl R, Ben Ya'acov A, Musseri M, Goldenberg R, Chammah Y, Cherki T, et al. Expression Profile of MicroRNAs in Breast Milk of Women With Inflammatory Bowel Disease: Correlation With Disease Activity and Medical Treatments. Inflammatory Bowel Diseases. 2025. doi:10.1093/ibd/izae290
BibTeX
@article{GolanGerstl2025,
author = {Golan-Gerstl, Regina and Ben Ya'acov, Ami and Musseri, Mirit and Goldenberg, Rosi and Chammah, Yehudit and Cherki, Tal and Reif, Shimon and Bar Gil Shitrit, Ariella},
title = {Expression Profile of MicroRNAs in Breast Milk of Women With Inflammatory Bowel Disease: Correlation With Disease Activity and Medical Treatments},
journal = {Inflammatory Bowel Diseases},
year = {2025},
doi = {10.1093/ibd/izae290}
}
EUVIMED